Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS: Intra-arterial UC-MSCs After Mechanical Thrombectomy in Acute Ischemic Stroke
NCT07913282Phase 1Not yet recruiting
- Sponsor
- Royan Cord Blood Bank
- Start
- Nov 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of WhartoCell in ischemic stroke (2 arms), sponsored by Royan Cord Blood Bank. Primary endpoints: Incidence of Serious Adverse Events at 6 months, Incidence of Adverse Events at 6 months and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
WhartoCell
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07913282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07913282.